Sunday, May 18, 2025
5/18/2025
The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesis - Abstract It has become well recognized that inflammation from chronic pancreatitis is associated an 8-fold increased risk for the development of pancreatic cancer. When cells are injured or stressed, they can transform to a cell with a different phenotype through a process called metaplasia. In the pancreas, acinar-ductal metaplasia (ADM) occurs with pancreatitis and this process is usually reversible. However, with chronic inflammation or maturation arrest, the ductal phenotype cells do not reverse to their normal acinar phenotype but may progress to pancreatic intraepithelial neoplasia (PanINs) and pancreatic cancer. There is a gap in our understanding of the mechanisms involved in this recovery or loss of the ability to recover. Our lab has been studying G-protein coupled receptors and found that the cholecystokinin-B receptor (CCK-BR) that is found in ductal cells but not acinar cells becomes expressed during chronic pancreatitis and PanIN formation, and is markedly over-expressed in pancreatic cancer. Treatment with a CCK-receptor antagonist, proglumide, hastens recovery of ADM, decreases inflammation, and restores the pancreas to a normal phenotype. In more advanced disease with PanINs or with pancreatic cancer, proglumide treatment also alters the pancreas extracellular matrix or tumor microenvironment, by decreasing collagen production from pancreatic stellate cells or cancer-associated fibroblasts and changing the immune cell signature to a more normal phenotype. We hypothesize that the CCK-BR signaling pathway is a novel and key pathway in pancreatic plasticity; strategies to suppress this pathway will decrease pancreatic cancer. Proglumide has already been tested in human subjects in a Phase 1 clinical trial and deemed to have a broad safety profile. In this proposal we will study the role of proglumide and the CCK-BR in pancreatic cell plasticity and how this pathway can be targeted to normalize the pancreatic phenotype and render it less oncogenic to prevent pancreatic cancer. The following aims are proposed: Aim #1, Determine how the CCK-BR signaling pathway is involved in acinar-ductal metaplasia; Aim #2, Examine how activation of the CCK-B receptor pathway modulates pancreatic stellate cells and if CCK- receptor blockade can change the phenotype to render the fibroblasts less carcinogenic; and Aim #3, Evaluate how activation of the CCK-BR induces tissue inflammation and polarization of immune cells. In this investigation, we will use murine models of pancreatitis in wild-type and in CCK-BR-knockout mice with state of the art techniques as laser microdissection of ADM and stroma, Reverse phase protein array, Mass Cytometry and RNA sequencing to understand plasticity of pancreatic cells. We will also examine the role of the CCK-BR on the pancreatic stellate cells in vitro using murine and human cells. Our goal is to understand how proglumide reprograms a metaplastic or dysplastic pancreas to a more normal phenotype and thus preventing development of pancreatic cancer.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).